Compare Mesoblast Limited (MESO) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Yum China Holdings Inc — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while Yum China Holdings Inc trades at $43.72 (market cap $15.09B). The key difference: Yum China Holdings Inc is far larger — about 7× Mesoblast Limited's market cap, and Yum China Holdings Inc pays a 2.64% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | YUMC | |
|---|---|---|
Market Cap | $2.17B | $15.09B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $57.95 |
52-Week Low | $12.88 | $40.18 |
Enterprise Value | $2.17B | $15.98B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
YUMC trades at $43.92, up 0.11% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $11.80B in 2025, and profitability remains solid with a 7.83% net margin. The acquisition of Pizza Hut China ownership is a strategic move expected to enhance margins.
The outlook is positive with strong analyst support (73.68% buy ratings), but risks include China's macroeconomic headwinds and competitive pressures. Valuation appears reasonable with a P/E of 16.81, suggesting potential for upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
